Xenon Pharmaceuticals XENE reported a loss of 84 cents per share for the fourth quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of 89 cents. The company had incurred a loss of 64 ...

Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today ...

Xenon Pharmaceuticals (($XENE)) has held its Q4 earnings call. Read on for the main highlights of the call. Xenon Pharmaceuticals’ recent earnings ...

Recompiled project, XenonRecomp does something similar, except for the PowerPC-equipped Microsoft Xbox 360 game console. Based around the triple-core IBM CPU codenamed ...

William Blair restated their outperform rating on shares of Xenon Pharmaceuticals (NASDAQ:XENE – Free Report) in a report ...

Wedbush lowered the firm’s price target on Xenon Pharmaceuticals (XENE) to $42 from $43 and keeps an Outperform rating on the shares. Most ...

Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Free Report) has earned an average rating of “Buy” from the nine ratings firms that are covering the company, Ratings reports. Nine equities research ...

VANCOUVER, British Columbia and BOSTON, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, ...

Xenon's discovery concluded an intense period of research on noble gases. Much heavier than neon and krypton, it had not been explicitly predicted, and was sufficiently rare to avoid chance detection.

BURNABY, British Columbia — BURNABY, British Columbia — Xenon Pharmaceuticals Inc. (XENE) on Thursday reported a loss of $65.7 million in its fourth quarter. On a per-share basis, the Burnaby, British ...

Detailed price information for Xenon Pharmaceuticals Inc (XENE-Q) from The Globe and Mail including charting and trades.